Akela Pharma awarded development contract at its PharmaForm subsidiary


    www.akelapharma.com
    Toronto Stock Exchange Symbol: AKL

    MONTREAL, June 5 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has been awarded a development and
manufacturing contract at its PharmaForm subsidiary located in Austin, Texas,
for development and manufacturing of a generic form of a commercial product
for an undisclosed pharmaceutical company. The contract is anticipated to
generate $1.5 - $2.0 M. in revenues over the next 12 - 18 months. The contract
includes technical transfer to support GMP manufacturing, process validation,
quality release testing and stability characterization. PharmaForm expects to
sign additional contracts with this client to support manufacture of clinical
supplies for an additional indication and commercial manufacturing in the near
future.
    "We are extremely proud to have been awarded this important contract.
This contract along with steady interest in our commercial manufacturing
services and expansion in our drug product development services validates our
growth strategy." said Dr. Michael Crowley, Vice President, Business
Development of PharmaForm.

    About PharmaForm:

    Headquartered in Austin, Texas, PharmaForm is a leading specialty
contract service provider offering a portfolio of innovative technologies in
drug product development, manufacturing and analytical testing. Through its
diverse offerings, PharmaForm delivers drug product solutions that help
clients reduce development costs and accelerate time-to-market. PharmaForm is
currently expanding its drug product pipeline based upon its expertise in
hot-melt extrusion and solids processing.

    About Akela Pharma Inc.:

    Akela Pharma is an integrated drug development company focused on
developing therapies for the growing multi-billion dollar inhalation and pain
markets. Its lead product, for the treatment of breakthrough cancer pain, is a
fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry
powder inhaler platform. Its pipeline also includes therapeutics for asthma,
COPD, growth hormone deficiencies and controlled substance abuse deterrent
formulations. PharmaForm, Akela's wholly owned subsidiary, is a leading
specialty contract service provider offering a portfolio of innovative
technologies in drug product development, manufacturing and analytical testing
to the pharmaceutical and biotechnology industries. Through its diverse
offerings, PharmaForm solutions help clients reduce development costs and
accelerate time-to-market.
    Akela's common shares trade on The Toronto Stock Exchange ("TSX") under
the symbol "AKL" with 21.6 million shares outstanding.

    This news release contains certain forward-looking statements that
reflect the current views and/or expectations of Akela Pharma Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
    %SEDAR: 00003466EF



For further information: visit Akela's website at www.akelapharma.com,
or contact: Frédéric Dumais, Vice-President, Investor Relations, (514)
315-3330 ext. 106, Fax: (514) 315-3325